Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (142)	8/18/1998 11:42:00 AM
From: Scott H. Davis	Read Replies (1) \| Respond to of 626

Thanks for the clinical update Greg. Good news is that the good news about the Phase III came on a up NAZ day, and in the A.M. Additional interested parties will read tonight. Big grin day, Scott

To: Abuckatatime who wrote (142)	8/18/1998 1:59:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 626

It's curious that, after all this time and all the frustrations, Fong et al. suddenly get anti-id to work for not just one antigen, but for a variety of them. Physicians are not necessarily serologists. That's not to say that these antibodies are not capable of eliciting anti-tumor responses, although I have my doubts. Some of biotech's most publicized failures have involved immunoglobulins that had no physiologically relevant affinity for the antigen that was supposedly used to induce them.